<DOC>
	<DOCNO>NCT00122226</DOCNO>
	<brief_summary>This randomize prospective study metabolic adverse event different type initial antiretroviral therapy HIV-1-infected men .</brief_summary>
	<brief_title>MEDICLAS Study ( Metabolic Effects Different Classes AntiretroviralS )</brief_title>
	<detailed_description>This randomize prospective study metabolic adverse event initial antiretroviral therapy HIV-1-infected men . The follow regimen compare : lopinavir-ritonavir + Combivir lopinavir-ritonavir + nevirapine ( nucleoside reverse transcriptase inhibitor [ NRTI ] -sparing ) . Prior start therapy 3 , 12 , 24 , 36 month thereafter distribution body fat bone density ( bioelectrical impedance analysis [ BIA ] , compute tomography [ CT ] dual energy x-ray absorptiometry [ DEXA ] ) , lipid spectrum , mitochondrial DNA ( peripheral blood mononuclear cell [ PBMCs ] adipose tissue biopsy ) vascular measurement perform . In addition , insulin sensitivity measure subgroup sixteen individual use hyperinsulinemic euglycemic clamp perform microvascular measurement . The aim study obtain prospective insight occurrence various aspect metabolic adverse event one hand compare NRTI-containing therapy NRTI-sparing therapy hand . The hypothesis NRTI-sparing arm , less metabolic vascular change observe NRTI contain regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Male Age 18 70 year . No prior use antiretroviral therapy Indication antiretroviral treatment accord common standard Female sex Body mass index ( kg/m2 ) &gt; 35 . Known history diabetes mellitus hyperlipidemia Use coenzyme A reductase inhibitor fibric acid derivative last 6 week inclusion Use follow medication : systemic corticosteroid , thiazide diuretic , calciumentry blocker , angiotensinconverting inhibitor , nitrate Use nandrolone testosterone Any disorder condition expect lead lessen compliance study protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-associated lipodystrophy syndrome</keyword>
</DOC>